Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diclofenac + gabapentin
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Topical, Oral
01
Overview
A combination of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), and gabapentin, a medication traditionally used to treat nerve pain. This combination exhibits synergistic effects in pain management, with potency approximately three times higher than expected from the addition of individual drug effects. It is used for various pain conditions including inflammatory pain, neuropathic pain, and postoperative pain.
02
Targets
CACNA2D2 (α2δ-2)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on diclofenac + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diclofenac + gabapentin.